TRCT
ANRO icon

Tower Research Capital (TRC)’s Alto Neuroscience ANRO Stock Holding History

Tower Research Capital (TRC)’s Portfolio ANRO Stock Details ANRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$52.7K Buy
1,996
+1,931
+2,971% +$44.7K ﹤0.01% 2689
2026
Q1 		$1.46K Sell
65
-1,922
-97% -$35.6K ﹤0.01% 4653
2025
Q4 		$35.4K Sell
1,987
-403
-17% -$5.08K ﹤0.01% 2691
2025
Q3 		$9.61K Sell
2,390
-228
-9% -$756 ﹤0.01% 4020
2025
Q2 		$5.76K Sell
2,618
-1,619
-38% -$3.85K ﹤0.01% 4151
2025
Q1 		$9.15K Buy
4,237
+1,545
+57% +$5.53K ﹤0.01% 3819
2024
Q4 		$11.4K Buy
2,692
+1,464
+119% +$9.14K ﹤0.01% 3720
2024
Q3 		$14K Buy
+1,228
New +$15K ﹤0.01% 3479
2024
Q2 		– Sell
-1,046
Closed -$16.1K – 6054
2024
Q1 		$16.1K Buy
+1,046
New +$16.4K ﹤0.01% 3207

Other funds holding ANRO

AWG
Alpha Wave Global New York $6.24B AUM 59.73% 1-Year Est. Return
CC
Commodore Capital New York $1.68B AUM 375.52% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $71.3B AUM 56.8% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
SSC
Spruce Street Capital New York $510M AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $462B AUM 39.16% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return

Tower Research Capital (TRC)'s ANRO Position: Q2 2026 in Review

Tower Research Capital (TRC) increased its Alto Neuroscience (ANRO) stake by 2,971% in Q2 2026, buying an estimated $44.7K and bringing the position to 1,996 shares worth $52.7K. The position accounts for ﹤0.01% of the portfolio, ranked #2689.

Tower Research Capital (TRC) first reported a position in ANRO in Q1 2024 and has held it in 9 quarters since. 114 funds tracked by Wall St. Rank hold ANRO as of Q2 2026.

  • Tower Research Capital (TRC) held 1,996 shares of Alto Neuroscience worth $52.7K as of Q2 2026.
  • Tower Research Capital (TRC) bought 1,931 Alto Neuroscience shares in Q2 2026, an estimated $44.7K.
  • Alto Neuroscience made up ﹤0.01% of Tower Research Capital (TRC)'s portfolio in Q2 2026, its #2689 holding.
  • Tower Research Capital (TRC) first reported a position in Alto Neuroscience in Q1 2024 and has held it in 9 quarters since.
  • 114 funds tracked by Wall St. Rank held Alto Neuroscience as of Q2 2026.

Based on Tower Research Capital (TRC)'s 13F filing for Q2 2026, filed 11 Aug 2026.